Evaluation of Malignancy Risk in 18F-FDG PET/CT Thyroid Incidentalomas.
FDG PET/CT
malignancy risk
thyroid incidentalomas
Journal
Diagnostics (Basel, Switzerland)
ISSN: 2075-4418
Titre abrégé: Diagnostics (Basel)
Pays: Switzerland
ID NLM: 101658402
Informations de publication
Date de publication:
07 Aug 2019
07 Aug 2019
Historique:
received:
15
07
2019
revised:
04
08
2019
accepted:
05
08
2019
entrez:
10
8
2019
pubmed:
10
8
2019
medline:
10
8
2019
Statut:
epublish
Résumé
Thyroid incidentalomas detected by 18 fluoro-2-deoxy-d-glucose (FDG)-positron emission tomography/computed tomography (PET/CT) are a real challenge for nuclear medicine physicians and clinicians. This study aimed to evaluate the risk of malignancy for patients with focal thyroid incidentalomas (TIs) diagnosed through FDG PET/CT. Data from 6900 patients, with a known primary tumor, who had an FDG PET/CT investigation performed were analyzed for the presence of incidental thyroid uptake. The focal TIs were reported, and the patients were referred for further investigation to the endocrinology department. There were 126 patients (1.82%) who presented with focal thyroid uptake, and for 87 of them, investigations were completed with ultrasonography (US), and for 29 with a fine needle aspiration biopsy (FNAB) procedure. Malignancy was detected in 7.93% (10/126) of cases. An arbitrary cutoff value of four was established for the standard uptake value lean body mass (SUVlbm Max) to differentiate the malignant nodules from the benign ones, and this value was significantly associated with malignancy (
Identifiants
pubmed: 31394887
pii: diagnostics9030092
doi: 10.3390/diagnostics9030092
pmc: PMC6787921
pii:
doi:
Types de publication
Journal Article
Langues
eng
Déclaration de conflit d'intérêts
The authors declare no conflict of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
Références
Am J Surg. 2017 May;213(5):950-957
pubmed: 28408111
Best Pract Res Clin Endocrinol Metab. 2008 Dec;22(6):901-11
pubmed: 19041821
Case Rep Endocrinol. 2014;2014:741262
pubmed: 24711931
Int J Cancer. 2015 May 1;136(9):2187-95
pubmed: 25284703
Nucl Med Commun. 2016 Dec;37(12):1290-1296
pubmed: 27612034
Hormones (Athens). 2019 Jun;18(2):145-149
pubmed: 30989578
Eur J Nucl Med Mol Imaging. 2014 Aug;41(8):1482-91
pubmed: 24781870
J Nucl Med. 2007 May;48(5):802-10
pubmed: 17475970
Korean J Radiol. 2018 Mar-Apr;19(2):342-351
pubmed: 29520193
J Otolaryngol Head Neck Surg. 2017 Mar 21;46(1):22
pubmed: 28320460
Clujul Med. 2017;90(2):147-153
pubmed: 28559697
Nucl Med Commun. 2009 Mar;30(3):240-4
pubmed: 19262287
Nucl Med Commun. 2016 Jul;37(7):715-20
pubmed: 26963467
J Clin Endocrinol Metab. 2012 Nov;97(11):3866-75
pubmed: 22904176
Thyroid. 2018 Jun;28(6):762-768
pubmed: 29759033
Surgery. 2003 Mar;133(3):294-9
pubmed: 12660642
Endocrine. 2019 May;64(2):203-208
pubmed: 30637562
Nat Rev Endocrinol. 2011 Jun 28;7(11):668-80
pubmed: 21709710
J Nucl Med. 2007 Jun;48(6):932-45
pubmed: 17504879
Thyroid. 2016 Jan;26(1):1-133
pubmed: 26462967
J Am Soc Cytopathol. 2017 Nov - Dec;6(6):217-222
pubmed: 31043290
Mol Imaging Radionucl Ther. 2017 Oct 3;26(3):93-100
pubmed: 28976331
Clin Endocrinol (Oxf). 2011 Oct;75(4):528-34
pubmed: 21575027
J Cancer Res Ther. 2018 Jul-Sep;14(5):989-993
pubmed: 30197336